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ABSTRACT
Purpose Doxorubicin (DOX) is a very effective anticancer
agent. However, in its pure form, its application is limited by
significant cardiotoxic side effects. The purpose of this study
was to develop a controllably activatable chemotherapy
prodrug of DOX created by blocking its free amine group
with a biotinylated photocleavable blocking group (PCB).
Methods An n-hydroxy succunamide protecting group on the
PCB allowed selective binding at the DOX active amine group.
The PCB included an ortho-nitrophenyl group for photo
cleavability and a water-soluble glycol spacer arm ending in a
biotin group for enhanced membrane interaction.
Results This novel DOX-PCB prodrug had a 200-fold
decrease in cytotoxicity compared to free DOX and could
release active DOX upon exposure to UV light at 350 nm.
Unlike DOX, DOX-PCB stayed in the cell cytoplasm, did not
enter the nucleus, and did not stain the exposed DNA during
mitosis. Human liver microsome incubation with DOX-PCB
indicated stability against liver metabolic breakdown.
Conclusions The development of the DOX-PCB prodrug
demonstrates the possibility of using light as a method of
prodrug activation in deep internal tissues without relying on
inherent physical or biochemical differences between the
tumor and healthy tissue for use as the trigger.
KEY WORDS prodrug.photocleavable.photoactivatable.
doxorubicin.toxicity
INTRODUCTION
Doxorubicin (DOX) is an effective antitumor antibiotic that
is used extensively in the treatment of different human
cancers, including breast cancer, soft tissue sarcomas, and
Hodgkin’s and non-Hodgkin’s lymphomas (1, 2). Although
it is one of the more potent chemotherapy agents known, its
clinical application is limited by its harmful side effects, the
most significant of which is its cardiotoxicity, which can
lead to cardiomyopathy and congestive heart failure (2–4).
Considerable work has been undertaken to chemically
modifyDOX and other chemotherapy agents withthe goalof
reducing their systemic toxicity. One such route is to create
prodrugs which exhibit reduced toxicity to healthy tissue and
can be transformed into pharmacologically active agents
specifically within the tumor region. (4–6). Several designs
have taken advantage of environmental differences between
the tumor tissue and normal tissue, such as hypoxia or low
pH, to trigger the prodrug transformation (7, 8). Some
prodrugs have been designed to be activated by enzymes
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elsewhere in the body (9–11). The degree of tumor specificity
for prodrug activation in these cases depends upon the
degree of difference between the tumor tissue and the
healthy tissue with respect to these parameters.
Some prodrug designs focus on tumor-specific antigens
that are expressed on the surface of the tumor cells.
Attaching antibodies to the chemotherapy agents that are
specific for those antigens excludes the agent from non-
targeted healthy cells. The transformation of the agent is
triggered upon antibody/antigen binding and internaliza-
tion into the cell, usually triggered by the low pH of the
intracellular endosome environment (12). These strategies
can achieve higher degrees of tumor-specific prodrug
activation with increasing amounts of knowledge about
the internal environment and the surface antigens specific
to a certain tumor. However, tumor cells are not
homogenous in their gene expression (13). This makes
targeting every single cell difficult. They are also not
homogenous in their physical location relative to the
tumor’s hypoxic or low-pH zones. Some cells can be
difficult to reach, especially with bulky prodrugs, due to
poor circulation networks within the tumor tissue. This
requires that the prodrug be activated to a very potent drug
which can affect cells in the general region of activation.
Instead of relying on inherentdifferences between the tumor
and the healthy tissue to activate prodrugs, it is possible to
modify the tumor environment and take advantage of those
artificial changes to differentiate the tumor region from the rest
of the body. One method is to administer therapeutic ionizing
radiation and use the small amount of reducing chemical
species that can be created through water lysis. These extra
reducing species could theoretically fill the role of reducing
enzymes in the activation of the prodrug as long as the
cleavable linker is sensitive enough to respond to small amounts
oftheactivespeciesproduced(14). Work has also been done to
demonstrate the feasibility of covalently attaching photoliable
blocking groups to paclitaxel with the capability of releasing
paclitaxel upon light exposure (15). However, the biological
consequences of attaching the blocking group and the activity
of the released paclitaxel have not been studied.
Another method is to use non-human enzymes to activate
the prodrug. This reduces the possibility of any undesired
prodrug activation outside the desired region as long as the
enzyme itself, or the gene encoding for the enzyme, can be
delivered to the tumor tissue specifically (16, 17).
From previous work in this field, a few prodrug
properties can be identified for use in maximizing the
effectiveness of the prodrug. It is desirable that the prodrug
be a modified version of a potent chemotherapy drug and
have greatly reduced toxicity compared to the drug itself.
The use of a trigger source which is external to the body
and localized specifically to the tumor tissue of interest
avoids relying on inherent properties of the tumor to
differentiate it from normal tissue. The ability of the
prodrug to enter cells and maintain its prodrug properties
is important to allow time for the circulating prodrug to
clear from the system. This ensures only the prodrug that
entered the targeted cells is trigged by the external source.
Once triggered to activate, the prodrug should release the
drug in its intact and pharmacologically active form.
The aim of this study was to design a prodrug that possess
these desirable properties. The final design was a caged form
of DOX created by blocking its free amine group with a
biotinylated photocleavable blocking group (PCB) (18). This
novel DOX-PCB prodrug can be activated upon exposure
to UV at 350 nm to release intact DOX. The photo-
cleavable properties come from the incorporation of an
o-nitrophenyl group (19). UV administered to the tissue
region of choice, possibly by use of fiber optics or miniature
UV light-emitting diodes, could trigger active DOX release
from the DOX-PCB prodrug specifically in this region.
The introduction of UV radiation to the deep internal
tissues through the use of implanted fiber optics or UV light-
emitting diodes would create a significant and controllable
differencebetween the tumor and the healthy tissue. The only
significant source of UV in the deep internal tissues of the
body would be the delivered UV, since only 1% of 360 nm
UV is transmitted through 1 mm of human skin due to
melanin content (20). The 350 nm light has significant
penetration through tissue that does not contain melanin
with minimal absorption (21). The 350 nm light also has
minimal absorption by DNA (22). The use of UV photo-
cleavable prodrugs, such as DOX-PCB, could allow for
activation of the prodrug just in the UV-exposed deep tissue
region. A higher degree of spatial and temporal control
could be achieved this way rather than relying solely on
inherent differences between the tumor and the healthy
tissue to act as the trigger. The effective spatial range of the
UV dose, and subsequent active DOX release, in the tissue
can be manipulated by adjusting intensity, duration of
exposure, and placement of the UV diode or fiber optic.
The scattering properties of the tissue would help ensure a
uniform exposure of the entire region of interest. The timing
of the administration of the UV dose can also be controlled
to occur when DOX-PCB reaches its most concentrated
levels in the tumor region. In this continuing investigation we
have demonstrated the feasibility of this approach.
MATERIALS AND METHODS
Materials
Doxorubicin hydrochloride (DOX) was obtained from
Qventas (Branford, CT, USA) and Sigma (St. Louis,
Doxorubicin Prodrug with Photolysis Activation 1849MO, USA). Water-soluble photocleavable biotin-NHS
(PCB) was purchased from Ambergen (Watertown, MA,
USA). The components of the synthesis buffer, NaCHO3
and NaOH, were from EMD (San Diego, CA, USA). The
NADPH regeneration system was purchased from BD
Biosciences (San Jose, CA, USA). The human liver
microsomes and the TOX2 In Vitro Toxicology XTT
Assay Kit were both purchased from Sigma (St. Louis,
MO, USA). The DMEM cell culture media and the
trypsin were purchased from Mediatech Inc. (Manassas,
VA, USA). The penicillin-streptomycin used in the
DMEM medias, the advanced MEM Media, and the
DMEM Media without phenol red were purchased from
Gibco (Invitrogen, Grand Island, NY, USA). The fetal
bovine serum used in the DMEM media solutions was
purchased from Hyclone (Logan, UT, USA). HPLC-grade
acetonitrile and methanol were purchased from Fisher
Scientific (Fairlawn, NJ, USA). The methanol-d4 and
deuterated dimethlyl sulfoxide (DMSO-d6) were pur-
chased from Cambridge Isotope Laboratories Inc. (And-
over, MA, USA). The preparative thin-layer silica gel
liquid chromatography plates were purchased from
Merck. The water used was first filtered with the Milli-Q
Plus System (Millipore Corporation, Bedford, USA). The
cell line used for the cytotoxicity studies was the human
lung cancer cell line A549 purchased from the American
Type Culture Collection (ATCC) (Manassas, VA, USA).
The PTK2 (Potorous tridactylus)k i d n e ye p i t h e l i a lc e l ll i n e
was originally purchased from the ATCC and kindly
provided by the Beckman Laser Institute (UC Irvine, CA).
Conjugation of DOX to PCB
DOX was dissolved in water to a 1.2 µM concentration. A
0.1 M NaCHO3/NaOH buffer at pH 9.3 was added to the
DOX solution to bring the total pH to 9.0. The DOX/
buffer solution was then added to 1 mg (1.2 µmoles) of dry
water-soluble photocleavable biotin (PCB) in a 1:1 molar
ratio. The reaction was stirred vigorously with a magnetic
Teflon-coated stir bar for 30 min. The DOX-PCB prodrug
product precipitated out. The nearly colorless supernatant
was removed, and the precipitate was dissolved in DMSO.
The synthetic scheme is shown in Fig. 1.
Purification of DOX-PCB
Purification was done by preparative thin-layer liquid
chromatography using a silica gel on a small scale for
initial characterization. Later, an HPLC semiprep purifi-
cation was used to obtain larger amounts of DOX-PCB at
a higher degree of purity for cell culture work and the
DOX-PCB UV stability study. The purification of DOX-
PCB in DMSO was done on an Agilent 1200 Series LC
(SantaClara,CA,USA)withaLuna5uC-18(2)100Acolumn
(250 mm×15 mm, with a 5 µm bore size) (Phenomenex,
Torrance, CA, USA). Solution A was 100% water, and
solution B was 100% MeOH. B was increased from 10-100%
over 20 min with a flow rate of 50 µL/min. Two isomeric
forms of DOX-PCB were observed to separate slightly from
each other on the column and were collected together in the
same sample. The two isomers were also collected separately
from one another, and no differences in cytotoxicity between
the twoforms were observed.The overall yield ofpure DOX-
PCB was 70%.
Characterization
The DOX-PCB compound was characterized by high
resolution mass spectrometry, HPLC/mass spectrometry,
and an absorption spectral analysis.
High resolution mass spectrometry was performed on a
Thermo Scientific LTQ Orbitrap XL mass spectrometer
with electrospray ionization source (Milford, MA, USA).
The sample of purified DOX-PCB was dissolved in a
mixture of DMSO/water (20/80, v/v).
The HPLC/mass spectrometry analysis was performed on
a Thermo Finnigan LCQdeca mass spectrometer (Milford,
MA, USA) using a Magic C-18 column (1.0 mm×150 mm)
(Michrom BioResources, Auburn, CA). Solution A was 2.5%
MeOH in water, and Solution B was 100% MeOH. B was
increasedfrom10–95%over20minandthenheldat95%for
5 min. The flow rate was 50 µL/min. The mass spectrometry
portion used electrospray ionization (ESI) in positive ion
mode. The sample of purified DOX-PCB was dissolved in a
mixture of DMSO/water (20/80, v/v).
An absorption spectrum was taken of a purified sample
of DOX-PCB in DMSO and of DOX in DMSO using a
NanoDrop ND-1000 Spectrophotometer (Wilmington, DE,
USA). The measurements of DOX and DOX-PCB (data
not shown) reveal that both compounds had an absorption
maxima at λ=485 nm from the DOX chromophore.
DOX-PCB had an absorption at 350 nm due to the
nitrophenyl group. This group enabled the photolysis
process to occur upon absorption of radiation at 350 nm.
The DOX-PCB spectra had the following 6 peaks: UV-
visible (abs. DMSO): 260, 287, 480, 500, 530, 584 nm ("1%
cm:
25.9, 14.6, 11.0, 11.0, 6.6, 2.0
g
100mlcm).
Release of Intact DOX
T w od i f f e r e n tm e t h o d sw e r eu s e dt od e t e r m i n et h a t
unaltered DOX was released from DOX-PCB.
The first was an HPLC/mass spectrometry analysis
where a solution of DOX in DMSO/water (10/90, v/v)
and two identical solutions of purified DOX-PCB in
DMSO/water (10/90, v/v) were prepared. One of the
1850 Ibsen et al.DOX-PCB samples was exposed to 120 sec of
2.19 mW/cm
2 UV created by a source consisting of a
mercury arc lamp with a Mercury Short Arc HBO bulb
from OSRAM (München, Germany) with a 330–380 nm
bandpass filter. The second sample was not exposed to
UV. All three samples were then analyzed using HPLC
using the same analysis parameters as described above for
the characterization.
The second study was a
1H NMR analysis to determine
if the free amine of DOX was restored after UV exposure.
The analysis was performed with Watergate water suppres-
sion on a JOEL ECA-500 device (Peabody, MA, USA)
500 MHz with 1000 scans for DOX-PCB. The sample
consisted of purified DOX-PCB in a solution of DMSO-
d6/water (10/90, v/v). An NMR analysis was first run using
this sample. The same DOX-PCB sample was then
irradiated with 240 s of UV from the same source as
described above. The exposure time was increased to 240 s
to ensure a high percentage of conversion to give a clear
signal from the free amine if present. A second NMR
O
O
NO2
S
HN NH
O
(CH2)4 NH
O
(CH2)2
O (CH2)2 O (CH2)2 NH (CH2)2
O
NH
O
O
N
O
O
OH
O OH
OH
O
O O
OH
O
OH
NH2
OCH3
+
NaCHO3/NaOH buffer pH 9.0
OH
O OH
OH
O
O O
OH
O
OH
NH
O
O
NO2
OCH3
S
HN NH
O
(CH2)4 NH
O
(CH2)2
O (CH2)2 O (CH2)2 NH (CH2)2
O
NH
O
OH
N
O O +
DOX
PCB
DOX-PCB
Fig. 1 Synthesis scheme for
DOX-PCB
Doxorubicin Prodrug with Photolysis Activation 1851analysis using the same parameters as before was taken on
this UV irradiated sample. A control sample of pure DOX
was also dissolved in DMSO-d6/water (10/90, v/v). More
DOX was used than DOX-PCB because DOX was more
readily available, and a high signal-to-noise ratio was
desired to give the best indication of the chemical shift
from the free amine protons. The same NMR analysis was
run on this DOX sample using only 16 scans since this
sample had a much higher effective concentration.
Cell Uptake and Cellular Localization
The differences in the intracellular localization between
DOX and DOX-PCB were studied using the PTK2
epithelial cell line. This cell line was chosen due to its
overall sensitivity to DOX and its natural ability to remain
flat during cell division, allowing the mitotic spindle and
chromosomes to be readily visible. This feature permitted
very clear observation of the interaction of DOX and
DOX-PCB with the chromosome material when the
nuclear membrane was intact and when it was disassembled
at different stages of mitosis. The red fluorescence of DOX
and DOX-PCB allowed for easy identification of their
intracellular localization. The PTK2 cells were obtained
already plated in sealed Rose Chambers incubating in
advanced MEM Media with 2% fetal bovine serum,
nonessential amino acids, 110 mg/L sodium pyruvate,
and without penicillin-streptomycin or L-Glutamine from
Gibco. A 4 ml solution of 5 µM DOX dissolved in the
above media was prepared as well as a 4 ml solution of
50 µM DOX-PCB. DOX-PCB was used at a higher
concentration because its toxicity was already known to be
significantly lower than that of free DOX, and it was of
interest to determine its intracellular localization. These
solutions were injected into the Rose chamber, replacing
the 1.8 ml of original media. The cells were allowed to
incubate for 2 h with the drugs before being analyzed using
fluorescence microscopy (see subsequent description). After
the initial fluorescence analysis, the DOX-PCB incubated
cells were then exposed to the UV source for 60 s. The cells
were allowed to incubate in this exposed media for 1 h
before being analyzed again by fluorescence microscopy.
To determine if the UV exposure affected the cells and
their behavior with the DOX-PCB, a sample of DOX-PCB
solution was exposed to 60 s of UV by itself and then was
injected into the media of a cell culture chamber.
Images of the live PTK2 cells were obtained using a
Zeiss Axiovert 200 M Microscope (Zeiss, Thornwood, NY)
with a 63x phase III, NA 1.4 oil immersion objective. An
HCred1 rhodamine filter cube from Chroma (Rockingham,
VT, USA) was used for the fluorescent images. All
microscope control and imaging utilized the RoboLase
system (23).
Cytotoxicity
The cell line used for the IC50 studies was the human lung
cancer cell line A549 purchased from the American Type
Culture Collection (ATCC) (Manassas, VA, USA). The
cells were grown on sodium pyruvate-free DMEM media
containing 4.5 g/L of glucose, L-glutamine, 10% Fetal
Bovine Serum, and penicillin-streptomycin. The adherent
cells were detached from the expansion flask substrate using
Trypsin (.25% T / 2.21 mM EDTA) and plated onto a 96-
well plate at a density of 10
4 cells per well with 100 µL of
media. The cells were allowed to adhere to the bottom of
each well overnight.
Experiments were run in two replicates under five
different conditions. The first condition was exposure to
pure DOX, the second was exposure to DOX-PCB with
no UV irradiation, the last three were exposure to
DOX-PCB with 2, 20, and 60 min of UV irradiation
from the same source used in the UV stability experi-
ments. The stock solutions of 15.1 mM DOX and
15.1 mM DOX-PCB in DMSO were diluted to
100 µM in media. A 1/3 serial dilution was then
performed to create media solutions that ranged from
100 µM to 1.7 nM. Pure media was used as the control
condition. At the 100 µM concentration there was no
observed precipitation of either DOX or DOX-PCB.
The IC50 of DOX-PCB was not reached at 100 µM
concentration, so a second experiment was run where the
maximum concentration of DOX and DOX-PCB was
1000 µM. The same method of one-third serial dilutions
as described above was used for the high concentration
IC50 experiment. No significant precipitation of DOX-
PCB occurred, although there was precipitation of DOX
at the 1000 µM concentration level.
The media of each well with adherent cells was then
replaced with the appropriate premixed media/drug
solution, causing minimal disturbance to the cells them-
selves. The cells were allowed to incubate at 37°C for 72 h.
After 72 h, an XTT cell viability assay was performed using
the In Vitro Toxicology Assay Kit (TOX2) from Sigma-
Aldrich using phenol red free DMEM Media containing
10% Fetal Bovine Serum and penicillin-streptomycin from
Gibco. Absorbance measurements were taken with a Tecan
Infinite M200 plate reader (San Jose, CA, USA). The
percent viability vs. dose curves were generated using the
PRISM 4.0 program from GraphPad Software Inc. (La
Jolla, CA, USA) with the sigmoidal dose-response (variable
slope) curve fit.
UV Stability Experiments
In order to understand the stability and release character-
istics of DOX from the DOX-PCB prodrug upon UV
1852 Ibsen et al.exposure, an HPLC/mass spectrometry analysis was per-
formed using an Agilent 1100 Series LC (Santa Clara CA,
USA) connected to an Agilent MSD G2445D (Santa Clara
CA, USA). The column used was a Supelco Discovery HS
C18 (5 cm×2.1 mm, with a 3 µM bore size) (Bellefonte,
PA, USA) and was maintained at a temperature of 20.0°C.
The detection wavelengths were λ1 250 nm and λ2 400 nm.
An 8 µL injection was used with a solvent mixture of
acetonitrile (ACN) and water with 0.1%TFA using a
gradient of 10–90% ACN.
First, a standard curve of total ion count peak values for
DOX was created using the above protocol and samples of
known DOX concentration from 0.01 µM to 100 µM in
10X increments in a DMSO/water (20/80, v/v) solution.
The peak value of the total ion count for each DOX
concentration was collected, and the data was fitted to a
Boltzman sigmoidal curve using the program PRISM 4.0
from GraphPad Software Inc. (La Jolla, CA, USA) for the
concentration range between 0.01 and 100 µM.
Duplicate samples of 100 µM DOX-PCB in DMSO/
water (20/80, v/v) in 10 µL amounts were prepared and
then exposed to a 1.8 mW/cm
2 UV source for different
durations of time from 0 to 10 min. The samples were
placed in an Optilux Microtest 96-well assay plate (BD
Biosciences, San Jose, CA, USA) with opaque black walls
and a clear bottom to prevent reflections of UV in the well,
ensuring more uniform and repeatable UV exposure to
each sample. The cleavage of DOX from DOX-PCB was
most sensitive to 350 nm. The peak of the total DOX ion
count for each sample was determined using the same
HPLC/mass spectrometry protocol as described. These
values were then fitted to the standard DOX curve to
determine the concentration of the released DOX.
Metabolic Stability Using Human Liver Microsomes
To test the metabolic stability of the DOX-PCB molecule,
a human liver microsome assay was run using the BD
Biosciences (San Jose, CA, USA) NADPH regeneration
system. The human liver microsomes were purchased from
Sigma and had a protein content of 20 mg/ml. They were
pooled from several different human donors. The following
protocol was adapted from the NADPH regeneration
system suggested protocol.
One assay was run with pure DOX and the other three
assays with DOX-PCB. The pure DOX assay acted as the
control by looking for the expected metabolite Doxorubi-
cinol, see Fig. 7d. All reagents were warmed to 37°C. The
assay solution consisted of 80 µL of 0.5 M KPO4,2 0µ Lo f
solution A (NADP+and Glc-6-PO4) from the NADPH
regeneration system kit, 4 µL of solution B (G6PDH) from
the NADPH regeneration system kit, 278 µL of H2O, and
8 µL of either an 10 mM solution of DOX or DOX-PCB in
DMSO. The sample of DOX-PCB used here was not
purified because the synthesis reaction went nearly to
completion with only a residual amount of DOX present.
To this solution was added 10 µL of the microsomes. The
samples were then incubated in a shaker at 37°C for
30 min.
At the end of 30 min, 400 µL of acetonitrile was
added to the reaction. The mixture was vortexed for
2 min to stop the reaction of the microsomes and extract
DOX and potential DOX-PCB metabolites from the
reaction mixture. The mixture was centrifuged until two
layers were obtained. The top acetonitrile layer was
removed and centrifuged. An HPLC/mass spectrometry
analysis was done on the filtered supernatant of the
acetonitrile layer using the same analysis protocol for the
UV stability study with the detection wavelength at
280 nm.
RESULTS
Preparation of the Photocleavable Prodrug DOX-PCB
We have introduced a photosensitive blocking group to
reduce the cytotoxicity and reactivity of the chemotherapy
drug Doxorubicin with the option of fully regaining these
effects upon UV irradiation. Binding the photocleavable
blocking group to the active amine within the DOX
structure takes advantage of the high reactivity of this
group to ensure that the blocking occurs selectively at this
controlled location. Attaching certain groups to the active
amine itself has been shown to significantly reduce the
toxicity of DOX (24). Choosing the correct linking
molecules attached to the photocleavable group can reduce
the drug’s toxicity through steric hindrance and also by
specific interactions with various intracellular compart-
ments and membranes. For the design of DOX-PCB, a
water soluble photocleavable biotinylated compound (PCB)
was chosen which included an ortho-nitrophenyl group for
its photo cleavability (25) and a water-soluble glycol spacer
arm ending in a biotin group for enhanced membrane
interaction. During synthesis, the photocleavable group was
protected with an n-hydroxy succunamide group (NHS)
which enabled its covalent attachment to the amine group
in the DOX structure. The synthetic scheme is shown in
Fig. 1.
Characterization of DOX-PCB
Characterization was performed on DOX-PCB to confirm
the structure of the compound proposed in Fig. 1. High-
resolution mass spectrometry of DOX-PCB found that it
had complexed with Na
+. The measured mass of DOX-
Doxorubicin Prodrug with Photolysis Activation 1853PCB-Na
+ was 1244.4329 m/z, and the theoretical mass
was 1244.4316 m/z. These two values are well within the
0.4% calibration error of the analysis and ensure confi-
dence that DOX-PCB had the proposed structure shown in
Fig. 1.
An HPLC/mass spectrometry analysis was performed on
DOX-PCB. First pure DOX was run and showed a single
peak at 22 minutes of elution (peak 1) as seen in Fig. 2a.
The analysis of DOX-PCB shown in Fig. 2b showed two
peaks at 26 and 27 min of elution (peaks 2 and 3). Both
peaks had the same characteristic mass of DOX-PCB.
These peaks most likely represented two stable diastereo-
isomeric forms of the compound (26). The biotin portion of
the PCB is chirally homogenous, but the stereo center at
the methylene group ortho to the nitro group is a mixture
of R and S (Ambergen Inc., personal communication). The
interaction of PCB with the hydrophobic portion of the
DOX ring structure affects the overall polarity of the two
diastereoisomers differently, allowing separation on the
C18 column. Both diastereoisomeric forms of DOX-PCB
were isolated, and no significant difference in cytotoxicity
between them was observed. All the studies described here
used DOX-PCB samples that combined the two peaks.
Release of Intact DOX
It is essential that DOX-PCB release active DOX upon UV
exposure so as to obtain the maximum therapeutic effect.
Substituents left on the DOX could significantly reduce its
toxicity and the overall effectiveness of the prodrug.
Releasing free DOX from the DOX-PCB conjugate is
based upon the photocleavable characteristic of the nitro-
phenyl group introduced by Patchornik (25). The mecha-
nism of photolysis has been adapted from established
mechanisms and is shown schematically in Fig. 3 (27).
Light absorption at 350 nm causes the electron config-
urations in the nitrophenyl group to rearrange, inducing
the formation of an unstable 5-membered ring with one of
the nitro group’s oxygen atoms. The destabilization and
rearrangement of this ring causes the cleavage, releasing the
carbamate group along with DOX. The carbamate under-
goes hydrolysis in aqueous conditions, producing CO2 and
free DOX.
ThereleaseoffreeactiveDOXfromDOX-PCBuponUV
exposure was confirmed by an LC Mass Spectrometry
analysis. The HPLC for the purified DOX is shown in
Fig. 2a. The mass spectrometry for peak 1 confirms the
presence of DOX. The HPLC for purified DOX-PCB with
no UV exposure is shown in Fig. 2b. Mass specs for peaks 2
and 3 confirm the presence of DOX-PCB. The HPLC for
the DOX-PCB sample that had been exposed to 120 s of
UV is shown in Fig. 2c. The mass spectrometry analysis
identified peak 1 as DOX, and peaks 2 and 3 as DOX-PCB.
The release of intact DOX was also confirmed by proton
NMR.AnNMRofDOXwastakenandisshowninFig.4a.I t
displayed a prominent peak at 5.27 ppm attributed to the
free amine protons under the solvent conditions of DMSO/
water (10/90, v/v). An NMR of a purified DOX-PCB
sample should not have a chemical shift peak from the two
amine protons due to the carbamate linkage. As expected,
the NMR of pure DOX-PCB shown in Fig. 4b demonstrat-
ed an absence of the 5.27 ppm peak. This same DOX-PCB
sample was then exposed to the UV. The NMR from the
sample after the UV exposure is shown in Fig. 4c. The peak
at 5.27 ppm was restored, indicating that free DOX was
released upon UV exposure.
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Fig. 2 HPLC analysis of DOX-PCB before and after UV exposure. a
Peak 1 contains pure DOX. b Peaks 2 and 3 both contain DOX-PCB in
two diastereoisomeric forms. c The HPLC of the DOX-PCB sample after
exposure to UV. The peak 1 containing DOX appears along with
shortened Peaks 2 and 3 containing DOX-PCB.
1854 Ibsen et al.Cell Uptake and Cellular Localization
The free DOX released from DOX-PCB needs to have the
same cellular localization properties as normal free DOX for
maximum therapeutic effect. DOX and DOX-PCB are
naturally fluorescent, and their localization can be monitored
over time in live PTK2 cells using both phase contrast images
(top row in Fig. 5) and fluorescent images of the same field
(bottom row of Fig. 5). The intracellular localization of DOX
was distinct from that of DOX-PCB. Within hours of
exposure, DOX entered the cells and was concentrated
almost exclusively in the nucleus as pointed out by the
Fig. 3 Mechanism of DOX-PCB
photolysis and product release
with subsequent hydrolysis to
produce free DOX and CO2.
Doxorubicin Prodrug with Photolysis Activation 1855arrows in Fig. 5a and b. The top cell of Fig. 5a was not
undergoing mitosis, and DOX penetrated the nuclear
membrane and associated with the chromatin most likely
through a DNA intercalation mechanism (28). It can be seen
that the cell in the middle of Fig. 5a was undergoing an
abnormal mitosis. The nuclear membrane was degraded,
and DOX strongly localized to the exposed chromosomes.
The abnormal-appearing mitosis was most likely caused by
the interference of DOX with the DNA replication
mechanisms. There were very few observations of cells
undergoing mitosis, all of which appeared abnormal.
DOX-PCB also entered the cell quickly. However, it did
not concentrate in the nucleus as pointed out by the arrows
in Fig. 5c and d. DOX-PCB appeared to preferentially
accumulate within the cell in regions around the nucleus.
Future studies using colocalization staining techniques will
help identify which cellular structures DOX-PCB interacts
with. The right-most cell is shown undergoing a normal-
appearing mitosis where the nuclear membrane has
disassembled. It is clear that DOX-PCB had been excluded
from the mitotic spindle and the associated chromosomes.
The DOX-PCB concentration was 10 times higher than
DOX, and the cells seemed much healthier and appeared
to be undergoing normal mitosis.
When the same DOX-PCB chamber of cells from Fig. 5c
and d was exposed to UV, the red fluorescence accumulated
in the nucleus 1 h after exposure as pointed out in Fig. 5e
and f. The free DOX that was released from DOX-PCB
appeared to be behaving similar to free DOX with its ability
to pass through the nuclear membrane and bind to the
chromatin. The DOX-PCB that was not photolysed by the
UV remained outside the nucleus. These cells appeared to
have pyknotic nuclei with a darkened nuclear envelope and
also appeared to have highly granulated cytoplasms, both
features of cell death. The UV dose received by the cells
themselves did not influence their interaction with DOX-
PBC. This was evidenced by the fact that control cells which
were not exposed to UV, but were incubated with a DOX-
PCB sample that was separately irradiated by UV, exhibited
the same behavior (data not shown).
Cytotoxicity
For the prodrug effect to be pharmacologically useful, the
DOX-PCB needs to show a greatly reduced toxicity com-
pared to that of DOX. The results of the cell proliferation
assay on A549 human lung cancer cells are shown in Fig. 6a.
The IC50 of the DOX sample was 1.2 µM. The IC50 of
DOX-PCB was over 200 times higher at 250 µM, indicating
a significant prodrug effect. The large prodrug effect of
DOX-PCB makes it a good candidate to reduce the
undesirable systemic side effects of DOX, especially the
cardiotoxicity. The observed lack of DOX-PCB interaction
with DNA helps to explain the significant reduction in the
cytotoxicity of DOX-PCB over that of DOX.
For the prodrug effect to be truly functional, the
toxicity of the DOX-PCB sample needs to increase
upon UV exposure and release fully active DOX with
Fig. 4 NMR analysis of the chemical shift for free DOX, pure DOX-
PCB, and DOX-PCB after UV exposure. a The NMR of DOX showed
the chemical shift for the two amine protons to be at 5.27 ppm (DMSO/
water, 10/90, v/v). b This peak was absent in a sample of pure DOX-
PCB. c After exposure to UV, the DOX-PCB sample had a restoration of
the 5.27 ppm peak indicating the release of free DOX.
1856 Ibsen et al.well-characterized potent bioactivity. Fig. 6b shows a
table of IC50 values for DOX-PCB samples exposed to the
UV for increasing amounts of time. The DOX-PCB
samples dissolved in media were exposed to the UV
separately and then incubated with the cells, so the cells
were never exposed to UV. As exposure time of the media
increased, the IC50 decreased, approaching that of free
DOX due to the increasing amounts of free DOX that
were released from the DOX-PCB.
UV Stability Experiments
The release characteristics of DOX from the DOX-PCB
prodrug had a linear relationship (R
2=0.99) with the
Fig. 5 Microscopy images of DOX and DOX-PCB localization within PTK2 kidney epithelial cells. Panels A, C, and E (top row)a r ep h a s ec o n t r a s t
i m a g e so ft h ec e l l s .P a n e l sB ,D ,a n dF( bottom row) are fluorescent images of the same field of view as the images directly above. (a, b)D O Xs t r o n g l y
associated with the chromosomes as pointed out by the arrows. (c, d) DOX-PCB entered the cells but did not associate with the chromosomes as
pointed out by the arrows. (e, f) When exposed to UV, free DOX was released from DOX-PCB and the chromosomes began to fluoresce as seen
pointed out by the arrows.
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Fig. 6 Cell viability results from DOX, DOX-PCB, and DOX-PCB exposed to increasing amounts of UV. a Cell viability curve for A549
human lung cancer cells exposed to DOX and DOX-PCB with no UV exposure. The IC50 for DOX was 1.2 µM. The IC50 of DOX-PCB with no
UV exposure was over 200 times higher at 250 µM. b This table shows the IC50 values of DOX-PCB samples after different amounts of UV
exposure. The DOX-PCB samples were dissolved in media, exposed to the UV, and then incubated with the cells, so the cells were not exposed
to UV. As UV exposure time increased, the IC50 value decreased approaching that of pure DOX due to the higher doses of free DOX released
from the DOX-PCB.
Doxorubicin Prodrug with Photolysis Activation 1857amount of UV exposure (data not shown). After exposure
to the 1.8 mW/cm
2 UV source for 10 min, 18% of the total
DOX-PCB content in a 100-µm sample was converted to
DOX. The release rate of intact DOX was 1.8 µM/min.
Metabolic Stability Using Human Liver Microsomes
To maintain control over the spatial location of DOX-PCB
activation, it is important that the only significant pathway of
activation be from UV exposure and not from normal
metabolic activity, especially from the liver. Incubation of
DOX-PCB with human liver microsomes indicates that the
compound is quite resistant to metabolic breakdown. Fig. 7a
shows the HPLC results of the LC Mass analysis of DOX-
PCB after incubation with the human liver microsomes. Peak
1 contains DOX-Cl, a residue most likely left over from the
synthesis. Peak 2 contains DOX-Na, which is again most
likely a residue from the synthesis. Peak 3 contains DOX-
PCB. Peak 4 contains DOX-PCB, most likely the second
isomer, as well as a mass spectrometry peak at 579 m/z with
the proposed structure shown in Fig. 7b. This 579 m/z
metabolite is not the DOX-Cl complex because it shows up
in the 10.2–10.5 min peak on the HPLC, whereas DOX-Na
and DOX-Cl showed up well before that. The precursor to
the 579 m/z metabolite was found in the first of three
replicates of this experiment with a mass of 587 m/z with the
proposed structure shown in Fig. 7c. The hydrolyzing
enzymes in the liver microsomes most likely cleaved the
DOX-PCB molecule producing the unstable 587 m/z
fragment which was then fully reduced to the 579 m/z
metabolite, much like DOX is reduced to Doxorubicinol
shown in Fig. 7d. The main 579 m/z metabolite was
produced in relatively small quantities and has a substituent
on the active amine. Although it is unknown what effect this
particular substituent will have on the toxicity of this
metabolite, it has been demonstrated that similar substituents
significantly reduce the toxicity of DOX (24).
The product of the microsome incubation of DOX was
Doxorubicinol. Doxorubicinol has previously been estab-
lished as the major metabolite of DOX with the structure
shown in Fig. 7d (29, 30). This served as a positive control
for the microsome protocol.
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Fig. 7 LC mass analysis of DOX-PCB incubated with human liver microsomes and the proposed structures of the resulting metabolites. a HPLC from
the LC mass analysis of the human liver microsome experiments. b Proposed structure for the 579 m/z DOX-PCB metabolite. c Proposed structure for
the 587 m/z DOX-PCB metabolite that might be the precursor for the 579 m/z metabolite. d Structure of Doxorubicinol.
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In this paper, we have developed a new photocleavable
prodrug for cancer therapy by incorporating the active
chemotherapy agent DOX with the photocleavable protect-
ing group PCB to form the adduct DOX-PCB. It has been
shown that DOX-PCB isover200 timeslesstoxicthanDOX,
and upon irradiation active DOX is released. With the use of
small light-emitting diodes or fiber optics to deliver controlled
localized doses of 350 nm light to desired tissue regions, it
should be possible to administer a systemic dose of the
prodrug and release active DOX only within the tumor
region.Theprodrughasthepotentialtoentercellsinitscaged
formwithoutbeingmetabolizedtoapharmacologically active
form. A systemic administration of the prodrug would allow it
toentercellsandremainintheregionofinterestevenafterthe
freely circulating prodrug has beencleared fromthesystem. It
is important to note that a control experiment was run where
the A549 cells were exposed to the 1.8 mW/cm
2 UV light
source alone with no reduction in cell viability compared to
control cells after 20 min of exposure. After 60 min of
exposure, 90% viability was observed, which might have
been contributed by the 334 emission peak from the
Mercury Arc lamp leaking through the lower end of the
330–380 nm bandpass filter (31). This shows that the main
effect of cell viability reduction would be from the released
DOX at the 60-min exposure limit.
The incorporation of the biotin moiety is intended to help
increasetheclearancerateofthefreelycirculatingDOX-PCB
just before UV exposure. Free DOX-PCB in the tumor
bloodstream at the time of UV exposure would release free
DOX into the circulation. Only DOX-PCB that is present
inside the tumor cells should be activated. The biotin on
DOX-PCBallowsforuseofaclearingagent,suchasmodified
versions of biotin-galactose-human serum albumin (32)o r
biotin-LC-NM-(GalNac)16 (33), where the biotin would be
replaced with streptavidin. These clearing agents very
effectively reduce the circulating blood concentration of the
target molecule and are designed to use the galactose residue
to trigger uptake by galactose receptors in hepatocytes where
the entire complex is metabolized. The human microsome
experiments indicate that the DOX-PCB drug will remain
intact through that process. The biotin end of the prodrug
will also help increase the clearance rate of the PCB
fragment created by the UV exposure.
The presence of the biotin on DOX-PCB should not
cause undesirable accumulation or protein binding in vivo as
has been shown with a compound comprised of biotin
bound to a chelated radioisotope (32). The biotin present
on this chelated radioisotope did not cause significant
accumulation in any particular tissue, including the liver.
The compound was rapidly cleared from the body through
the renal system.
The use of photocleavable prodrugs offers an exciting
new avenue of investigation in reducing the systemic side
effects of chemotherapy drugs and other therapeutic agents
while increasing their effectiveness in the desired tissue
region. Future work will focus on extensive in vivo
characterization, including in vivo stability of DOX-PCB,
as well as its possible therapeutic effectiveness.
CONCLUSION
One strategy to reduce the toxic side effects of chemotherapy
agentsistomakeprodrugsbychemicallymodifyingtheagents
so as to reduce their overall toxicity, but also allow them to be
activated back to a therapeutic state in the tumor tissue. One
of the challenges is to differentiate the tumor from the healthy
tissue in order to effectively trigger the prodrug only in the
tumor. The triggers of many prodrug designs rely on inherent
biochemicaldifferencesbetween thetumorand healthy tissue.
These differences can be very subtle, and often healthy tissues
within the body will have the same biochemistry as the tumor.
To avoid the undesirable activation of the prodrug in these
untargeted tissues, an artificial difference can be created
within the tumor tissue from a source external to the body.
ThetriggerconsideredhereisUVradiationat350nm.Thisis
at the very low energy end of the UV spectrum with good
tissuepenetrationandlittleinteractionwithDNAandprotein.
A new prodrug of doxorubicin (DOX-PCB) is described that
can be converted to the active drug upon exposure to UV at
350 nm. It was formed by conjugating a photocleavable
blocking group to the sugar amine group of DOX. DOX-
PCBwasshowntohaveasignificantreductionintoxicityover
free DOX with a 200-fold lower IC50 in cell viability tests.
One of the possible reasons for the lower toxicity is that the
PCB portion blocks DOX-PCB from intercalating with
DNA, which is a main mode of action for DOX. DOX-
PCB was shown to be stable in a human microsome
experiment, indicating that DOX will not be released in a
significant amount due to metabolic conversion. DOX-PCB
was shown to release biologically active doxorubicin upon
exposure to UV at 350 nm, increasing the cytotoxicity of the
entire sample. It is possible to deliver UV only to the tumor
region using UV fiber optics or implantable UV LEDs. This
could cause the activation of systemically administered
DOX-PCB only in the tumor, thereby reducing systemic
side effects.
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